Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03775044 · ClinicalTrials.gov registry record · NA
Assessment of Medherent Medication Management Device and Adherence Platform
A NA study of Medication Adherence and Mental Health Disorder, sponsored by Terrapin Pharmacy.
- Active
- Registry status
- NA
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT03775044: Active NA study of Medication Adherence and Mental Health Disorder, sponsored by Terrapin Pharmacy.
NCT03775044 is a NA study of Medication Adherence and Mental Health Disorder that is active but no longer recruiting, run by Terrapin Pharmacy. The registered enrollment target is 150 participants, below the 1,654-participant average among 52 other Medication Adherence trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03775044, a NA study of Medication Adherence and Mental Health Disorder, is active but no longer recruiting, sponsored by Terrapin Pharmacy.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
This study uses a stepped wedge designs to estimate the effect of using the Medherent Medication Management Device on medication adherence for a population of 150 individuals who are diagnosed with serious mental illness.
Primary Outcome
Brief Evaluation of Medication Influences and Beliefs (BEMIB) is an 8-item scale. Total scores range from 0 to 32 with higher scores indicating more negative beliefs about medications.
Conditions Studied
Interventions
- DEVICE Medherent Device
Study Locations (1)
Maryland
- Terrapin Pharmacy - Annapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2023-03-31 |
| Phase | NA |
What the registry record for NCT03775044 still lists
NCT03775044 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 1,654-participant average among 52 other Medication Adherence trials with a reported enrollment target (91% lower).
The record links to 2 conditions, with Medication Adherence appearing as the primary indexed condition, and to 1 intervention - of which Medherent Device is the first listed.
NCT03775044 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT03775044 about?
NCT03775044 is a clinical study titled "Assessment of Medherent Medication Management Device and Adherence Platform". This study uses a stepped wedge designs to estimate the effect of using the Medherent Medication Management Device on medication adherence for a population of 150 individuals who are diagnosed with serious mental illness.
What is the current status of trial NCT03775044?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2019-05-01. Estimated completion is 2023-03-31.
What conditions does trial NCT03775044 study?
This clinical trial studies the following conditions: Medication Adherence, Mental Health Disorder.
What interventions are being tested in trial NCT03775044?
The interventions under investigation include: Medherent Device (DEVICE).
Who is sponsoring clinical trial NCT03775044?
This trial is sponsored by Terrapin Pharmacy, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03775044 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Medication Adherence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03775044's enrollment target sits among peer trials
150 25th of 52 higher than 26 of 52 other Medication Adherence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Medication Adherence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Mobile Gaming App to Improve Adherence to PrEP
RECRUITING · NA
-
1MoreStep: An Intervention to Increase HIV Care Engagement and Reduce Intimate Partner Violence Among Black Women Living With HIV
RECRUITING · NA
-
Medication Adherence Program
RECRUITING · NA
-
Improving Medication Adherence Using Family-focused and Literacy-sensitive Strategies
RECRUITING · NA
-
Refinement and Testing of Recruitment Methodology for Behavioral Medication Adherence Interventions Using Behavioral Science-based Approaches
RECRUITING · NA
-
Mobile Cued Adherence Therapy (mCAT) for Blood Pressure Medication
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI